These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1129 related articles for article (PubMed ID: 34887858)
21. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis]. Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041 [TBL] [Abstract][Full Text] [Related]
22. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma. Yang Q; Gong H; Liu J; Ye M; Zou W; Li H Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696 [TBL] [Abstract][Full Text] [Related]
23. A gene expression-based immune signature for lung adenocarcinoma prognosis. Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138 [TBL] [Abstract][Full Text] [Related]
24. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma. Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123 [TBL] [Abstract][Full Text] [Related]
25. Machine-learning and combined analysis of single-cell and bulk-RNA sequencing identified a DC gene signature to predict prognosis and immunotherapy response for patients with lung adenocarcinoma. Zhang L; Guan M; Zhang X; Yu F; Lai F J Cancer Res Clin Oncol; 2023 Nov; 149(15):13553-13574. PubMed ID: 37507593 [TBL] [Abstract][Full Text] [Related]
26. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma. Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465 [TBL] [Abstract][Full Text] [Related]
27. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. Zengin T; Önal-Süzek T J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117 [TBL] [Abstract][Full Text] [Related]
28. System analysis of Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116 [TBL] [Abstract][Full Text] [Related]
29. Comprehensive Analysis of Immune Implication and Prognostic Value of Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W Front Oncol; 2021; 11():798425. PubMed ID: 35047409 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive analyses of a CD8 Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525 [TBL] [Abstract][Full Text] [Related]
31. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma. Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701 [TBL] [Abstract][Full Text] [Related]
32. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma. Yang Y; Wang M; Liu B J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601 [TBL] [Abstract][Full Text] [Related]
33. Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients. Zhang T; Yang H; Sun B; Yao F Aging (Albany NY); 2021 Jan; 13(3):3819-3842. PubMed ID: 33428598 [TBL] [Abstract][Full Text] [Related]
34. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC. Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446 [TBL] [Abstract][Full Text] [Related]
35. A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma. Zhou W; Zhang W BMC Cancer; 2022 Jun; 22(1):694. PubMed ID: 35739504 [TBL] [Abstract][Full Text] [Related]
36. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns. Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675 [TBL] [Abstract][Full Text] [Related]
37. Myeloid cell differentiation-related gene signature for predicting clinical outcome, immune microenvironment, and treatment response in lung adenocarcinoma. Wu D; Liu Y; Liu J; Ma L; Tong X Sci Rep; 2024 Jul; 14(1):17460. PubMed ID: 39075165 [TBL] [Abstract][Full Text] [Related]
38. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma. Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077 [TBL] [Abstract][Full Text] [Related]
39. Multi‑omics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma. Xu S; Chen X; Ying H; Chen J; Ye M; Lin Z; Zhang X; Shen T; Li Z; Zheng Y; Zhang D; Ke Y; Chen Z; Lu Z BMC Cancer; 2024 Sep; 24(1):1138. PubMed ID: 39267056 [TBL] [Abstract][Full Text] [Related]
40. Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC). Zhang L; Chen J; Cheng T; Yang H; Li H; Pan C J Cancer; 2020; 11(17):4965-4979. PubMed ID: 32742444 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]